The pharmaceutical research industry has gone through a major transformation over the past 15 years. In 2010, large pharmaceutical companies controlled a major portion of global drug development. By 2026, smaller biotech and emerging biopharma companies have become the primary drivers of innovation across the global R&D pipeline.
The shift reflects changing investment patterns, advances in biotechnology, growing interest in precision medicine, and the rapid rise of AI-powered drug discovery platforms. Today, thousands of smaller companies are developing highly targeted therapies in areas such as oncology, rare diseases, gene therapy, and RNA-based medicines.
Global Pipeline Expansion Accelerated After 2010
The overall pharmaceutical pipeline has expanded significantly during the last decade. Global active drug candidates increased from fewer than 10,000 compounds in the early 2010s to more than 22,000 candidates by 2025–2026.
Several factors contributed to this growth:
- Increased venture capital funding for biotech startups
- Faster development of targeted therapies
- Growth in orphan drug research
- Expansion of cell and gene therapy programs
- AI integration into early-stage drug discovery
- Strong partnership activity between biotech firms and large pharma companies
The industry also became more decentralized. Instead of a few multinational corporations dominating innovation, smaller specialized companies now contribute the majority of early-stage research programs.
Pipeline Share by Company Size
The balance of pipeline ownership changed dramatically between 2010 and 2026.
| Company Type | Estimated Pipeline Share (2010) | Pipeline Share (2026) |
|---|---|---|
| Large Pharmaceutical Companies | 40% | 23% |
| Emerging Biopharma Companies | 45% | 65%-67% |
| Mid-sized Pharma Companies | 10% | 8%-10% |
| Small Pharma & Academic Institutions | 5% | 4%-6% |
Emerging biopharma companies now control nearly two-thirds of the global development pipeline. These firms are generally defined as companies generating less than US$500 million in annual revenue and spending under US$200 million annually on R&D activities.
Emerging Biopharma Became the Industry’s Innovation Engine
Smaller biotech firms are now responsible for a large share of scientific breakthroughs entering clinical development. Many of these companies focus on highly specialized therapeutic areas instead of broad commercial drug portfolios.
Companies such as Moderna, BioNTech, Beam Therapeutics, Recursion Pharmaceuticals, and Argenx expanded rapidly through innovation-focused pipelines.
The success of mRNA vaccines during the COVID-19 period also accelerated investor confidence in biotechnology platforms. This led to record biotech financing activity between 2020 and 2024.
China also became an increasingly important contributor to global pharmaceutical innovation. Chinese biotech companies significantly increased their share of the worldwide emerging biopharma pipeline, supported by government investment, growing research infrastructure, and international licensing deals.
Large Pharma Still Dominates Commercialization
Although smaller firms now lead early innovation, major pharmaceutical corporations continue to dominate large-scale clinical trials, manufacturing, regulatory operations, and global commercialization.
Companies including Pfizer, Roche, Novartis, AstraZeneca, and Bristol Myers Squibb still maintain some of the industry’s largest late-stage development portfolios.
Recent pipeline tracking data showed:
- Novartis managed approximately 97 drugs in development
- Roche maintained around 96 pipeline assets
- AstraZeneca operated nearly 88 active programs
- Pfizer held roughly 76 development candidates
However, many large pharmaceutical companies increasingly depend on acquisitions, licensing agreements, and partnerships with smaller biotech firms to strengthen their pipelines.
Oncology Remains the Largest R&D Segment
Cancer research continues to dominate pharmaceutical innovation worldwide. Oncology now represents nearly 39% of all new drug candidates entering development globally.
Rare disease therapies account for another major portion of pipeline growth, supported by regulatory incentives and growing demand for personalized medicine.
Some of the fastest-growing technology areas in 2026 include:
- Cell and gene therapy
- RNA therapeutics
- Antibody-drug conjugates (ADCs)
- CRISPR gene editing
- AI-assisted drug discovery
- Precision oncology platforms
AI-based drug discovery is becoming one of the most important trends in pharmaceutical R&D. Companies using machine learning platforms are improving target identification, reducing screening timelines, and accelerating preclinical development.
Access our exclusive, data-rich dashboard dedicated to the life science sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium